The immunology of psoriasis: From the basic research to the bedside;A pikkelysömör immunológiája: Az alapkutatástól a betegágyig

Orvosi Hetilap

Volumn 147, Issue 46, 2006, Pages 2213-2220

  Gyulai, Rolland ^a,b   Kemény, Lajos ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b NONE   (Hungary)

Author keywords

Animal disease models; Dermatology; Drug therapy; Immune system; Psoriasis; T lymphocytes

Indexed keywords

ALEFACEPT; AZATHIOPRINE; CALCIPOTRIOL; CHEMOKINE; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; DITHRANOL; EFALIZUMAB; ETANERCEPT; ETRETIN; ETRETINATE; HYDROXYUREA; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIMECROLIMUS; PSORIASIN; SALICYLIC ACID DERIVATIVE; TACALCITOL; TACROLIMUS; TAZAROTENE; DERMATOLOGICAL AGENT; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; KERATOLYTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; AUTOIMMUNE DISEASE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CHROMOSOME 1; CHROMOSOME 16Q; CHROMOSOME 17Q; CHROMOSOME 19P; CHROMOSOME 1P; CHROMOSOME 3Q; CHROMOSOME 4Q; CHROMOSOME 6P; CLIMATOTHERAPY; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; EXCIMER LASER; EXPERIMENTAL MODEL; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOGENESIS; INNATE IMMUNITY; KERATINOCYTE; MORBIDITY; PATHOPHYSIOLOGY; PATIENT CARE; PHOTOTHERAPY; PSORIASIS; PUVA; REGULATORY T LYMPHOCYTE; TH1 CELL; AUTOIMMUNITY; CELLULAR IMMUNITY; GENETICS; IMMUNOLOGY; MEDICAL RESEARCH; PATHOLOGY; REVIEW;

ACITRETIN; ADRENAL CORTEX HORMONES; ANTHRALIN; ANTIBODIES, MONOCLONAL; AUTOIMMUNITY; BIOMEDICAL RESEARCH; CELL DIFFERENTIATION; CELL PROLIFERATION; CYCLOSPORINE; DERMATOLOGIC AGENTS; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; KERATINOCYTES; KERATOLYTIC AGENTS; METHOTREXATE; PSORIASIS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, REGULATORY; ULTRAVIOLET THERAPY;

EID: 34249665496     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Allen, M. H., Veal, C., Faassen, A. és mtsai: A non-HLA gene within the MHC in psoriasis. Lancet, 1999, 353, 1589-1590.
2. Asumalahti, K., Veal, C., Laitinen, T. és mtsai: Coding haplotype analysis supports HCR as the putative susceptibility gene for psoriasis at the MHC PSORS1 locus. Hum. Mol. Genet., 2002, 11, 589-597.
3. Bachelez, H., Flageul, B., Dubertret, L. és mtsai: Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4. J. Autoimmun., 1998, 11, 53-62.
4. Bata-Csörgo, Z., Hammerberg, C., Voorhees, J. J. és mtsai: Flow cytometric identification of proliferative subpopulations within normal human epidermis and the localization of the primary hyper-proliferative population in psoriasis. J. Exp. Med., 1993, 178, 1271-1281.
5. Bata-Csögo Z., Hammerbery, C., Voorhees, J. J. és mtsai: Kinetics and regulation of human keratinocyte stem cell growth in short- term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J. Clin. Invest., 1995, 95, 317-327.
6. Bónis, B., Kemény, L., Dobozy, A. és mtsai: 308 nm UVB excimer laser for psoriasis. Lancet, 1997, 350, 1522.
7. Bour, H., Puisieux, I., Even, J. és mtsai: T-cell repertoire analysis in chronic plaque psoriasis suggests an antigen-specific immune response. Hum. Immunol., 1999, 60, 665-676.
8. Boyman, O., Hefti, H. P., Conrad, C. és mtsai: Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J. Exp. Med., 2004, 199, 731-736.
9. Burden, A. D., Javed, S., Bailey, M. és mtsai: Genetics of psoriasis: paternal inheritance and a locus on chromosome 6p. J. Invest. Dermatol., 1998, 110, 958-960.
10. Capon, F., Munro, M., Barker, J. és mtsai: Searching for the major histocompatibility complex psoriasis susceptibility gene. J. Invest. Dermatol., 2002, 118, 745-751.
11. Craven, N. M., Jackson, C. W., Kirby, B. és mtsai: Cytokine gene polymorphisms in psoriasis. Br. J. Dermatol., 2001, 144, 849-853.
12. Detmar, M., Brown, L. F., Claffey, K. P. és mtsai: Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J. Exp. Med., 1994, 180, 1141-1146.
13. Eastmond, C. J., Wright, V.: The nail dystrophy of psoriatic arthritis. Ann. Rheum. Dis., 1979, 38, 226-228.
14. Eedy, D. J., Burrows, D., Bridges, J. M. és mtsai: Clearance of severe psoriasis after allogenic bone marrow transplantation. B., 1990, 300, 908.
15. Ellis, C. N., Krueger, G. G.: Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N. Engl. J. Med., 2001, 345, 248-255.
16. Farber, E. M., Nall, M. L.: Epidemiology: natural history and genetics. In Psoriasis. Szerk.: Roenigk, H. H., Maibach, H. I. Marcel Dekker, New York. 1998, 107-158. old.
17. Farkas, A., Kemény, L., Szony, B. J. és mtsai: Dithranol upregulates IL-10 receptors on the cultured human keratinocyte cell line HaCaT. Inflamm. Res., 2001, 50, 44-49.
18. Ferrandiz, C., Pujol, R. M., Garcia-Patos, V. és mtsai: Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J. Am. Acad. Dermatol., 2002, 46, 867-873.
19. Gardembas-Pain, M., Ifrah, N., Foussard, C. és mtsai: Psoriasis after allogeneic bone marrow transplantation. Arch. Dermatol., 1990, 126, 1523.
20. Gladman, D. D., Anhorn, K. A., Schachter, R. K. és mtsai: HLA antigens in psoriatic arthritis. J. Rheumatol., 1986, 13, 586-592.
21. Gladman, D. D., Antoni, C., Mease, P. és mtsai: Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann. Rheum. Dis., 2005, 64 Suppl 2, ii14-17.
22. Gottlieb, A. B., Evans, R., Li, S. és mtsai: Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol., 2004, 51, 534-542.
23. Green, A. C.: Australian Aborigines and psoriasis. Australas. J. Dermatol., 1984, 25, 18-24.
24. Helms, C., Cao, L., Krueger, J. G. és mtsai: A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat. Genet., 2003, 35, 349-356.
25. Hohler, T., Kruger, A., Schneider, P. M. és mtsai: A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J. Invest. Dermatol., 1997, 109, 562-565.
26. Kemény, L., Ruzicka, T., Braun-Falco, O.: Dithranol: a review of the mechanism of action in the treatment of psoriasis vulgaris. Skin Pharmacol., 1990, 3, 1-20.
27. Koreck, A., Surányi, A., Szony, B. J. és mtsai: CD3+CD56+ NK T cells are significantly decreased in the peripheral blood of patients with psoriasis. Clin. Exp. Immunol., 2002, 127, 176-182.
28. Krueger, G., Koo, J., Lebwohl, M. és mtsai: The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol., 2001, 137, 280-284.
29. Lavaroni, G., Kokelj, F., Pauluzzi, P. és mtsai: The nails in psoriatic arthritis. Acta Derm. Venereol. Suppl. (Stockh), 1994, 186, 113.
30. Lebwohl, M., Tyring, S. K., Hamilton, T. K. és mtsai: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med., 2003, 349, 2004-2013.
31. Leonardi, C. L., Papp, K. A., Gordon, K. B. és mtsai: Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J. Am. Acad. Dermatol., 2005, 52, 425-433.
32. Lomholt, G.: Prevalence of Skin Diseases in a Population; a Census Study from the Faroe Islands. Dan. Med. Bull., 1964, 11, 1-7.
33. Mossner, R., Kingo, K., Kleensang, A. és mtsai: Association of TNF -238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris. J. Invest. Dermatol., 2005, 124, 282-284.
34. Mueller, W., Herrmann, B.: Cyclosporin A for psoriasis. N. Engl. J. Med., 1979, 301, 555.
35. Novák, Z., Bónis, B., Baltás, E. és mtsai: Xenon chloride ultraviolet B laser is more effective in treating psoriasis and in inducing T cell apoptosis than narrow-band ultraviolet B. J. Photochem. Photobiol. B, 2002, 67, 32-38.
36. Owen, C. M., Chalmers, R. J., O'Sullivan, T. és mtsai: Antist-reptococcal interventions for guttate and chronic plaque psoriasis. Cochrane Database Syst. Rev., 2000, CD001976.
37. Papp, K. A., Tyring, S., Lahfa, M. és mtsai: A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Dermatol., 2005, 152, 1304-1312.
38. Pauls, K., Schon, M., Kubitza, R. C. és mtsai: Role of integrin alphaE (CD103)beta7 for tissue-specific epidermal localization of CD8+ T lymphocytes. J. Invest. Dermatol., 2001, 117, 569-575.
39. Reich, K., Nestle, F. O., Papp, K. és mtsai: Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet, 2005, 366, 1367-1374.
40. Sano, S., Chan, K. S., Carbajal, S. és mtsai: Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med., 2005, 11, 43-49.
41. Sonkoly, E., Bata-Csörgo, Z., Pivarcsi, A. és mtsai: Identification and characterization of a novel, psoriasis susceptibility-related noncoding RNA gene, PRINS. J. Biol. Chem., 2005, 280, 24159-24167.
42. Speckman, R. A., Wright Daw, J. A., Helms, C. és mtsai: Novel immunoglobulin superfamily gene cluster, mapping to a region of human chromosome 17q25, linked to psoriasis susceptibility. Hum. Genet., 2003, 112, 34-41.
43. Sugiyama, H., Gyulai, R., Toichi, E. és mtsai: Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J. Immunol., 2005, 174, 164-173.
44. Széll M., Bata-Csörgo Z., Sonkoly E. és mtsai: Genomikai kutatások a borgyógyászatban. Magyar Tudomány, 2005, 688.
45. Széll, M., Bata-Csörgo, Z., Koreck, A. és mtsai: Proliferating keratinocytes are putative sources of the psoriasis susceptibility-related EDA+ (extra domain A of fibronectin) oncofetal fibronectin. J. Invest. Dermatol., 2004, 123, 537-546.
46. Tsankov, N., Angelova, I., Kazandjieva, J.: Drug-induced psoriasis. Recognition and management. Am. J. Clin. Dermatol., 2000, 1, 159-165.
47. Wrone-Smith, T., Nickoloff, B. J.: Dermal injection of immunocytes induces psoriasis. J. Clin. Invest., 1996, 98, 1878-1887.
48. Zachariae, H.: Prevalence of joint disease in patients with psoriasis: implications for therapy. Am. J. Clin. Dermatol., 2003, 4, 441-447.